To the top

Page Manager: Webmaster
Last update: 9/11/2012 3:13 PM

Tell a friend about this page
Print version

Efficacy and Safety of th… - University of Gothenburg, Sweden Till startsida
Sitemap
To content Read more about how we use cookies on gu.se

Efficacy and Safety of the Glycine Transporter-1 Inhibitor Org 25935 for the Prevention of Relapse in Alcohol-Dependent Patients: A Randomized, Double-Blind, Placebo-Controlled Trial

Journal article
Authors Andrea deBejczy
K. R. Nations
A. Szegedi
J. Schoemaker
F. Ruwe
Bo Söderpalm
Published in Alcoholism-Clinical and Experimental Research
Volume 38
Issue 9
Pages 2427-2435
ISSN 0145-6008
Publication year 2014
Published at Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry
Pages 2427-2435
Language en
Links dx.doi.org/10.1111/acer.12501
Keywords Org 25935, Alcohol Dependence, Alcohol Relapse Prevention, Glycine Transporter Inhibitor, RAT NUCLEUS-ACCUMBENS, ETHANOL INTAKE, DOPAMINE RELEASE, COMBINED-PHARMACOTHERAPIES, BEHAVIORAL INTERVENTIONS, USE DISORDERS, ACAMPROSATE, RECEPTORS, NALTREXONE, DECREASES, Substance Abuse
Subject categories Clinical Medicine

Abstract

Background: Org 25935 is a glycine transporter inhibitor that increases extracellular glycine levels and attenuates alcohol-induced dopaminergic activity in the nucleus accumbens. In animal models, Org 25935 has dose-dependent effects on ethanol intake, preference, and relapse-like behavior without tolerance. The current study aimed to translate these animal findings to humans by examining whether Org 25935 prevents relapse in detoxified alcohol-dependent patients. Methods: This was a multicenter, randomized, double-blind, placebo-controlled clinical trial. Adult patients diagnosed with alcohol dependence were randomly assigned to receive Org 25935 12 mg twice a day or placebo for 84 days. The primary end point was percentage heavy drinking days (defined as >= 5 standard drinks per day for men and >= 4 for women). Secondary end points included other measures of relapse-related drinking behavior (e. g., drinks per day, time to relapse), as well as measures of global functioning, alcohol-related thoughts and cravings, and motivation. Results: A total of 140 subjects were included in the intent-to-treat analysis. The trial was stopped approximately midway after a futility analysis showing that the likelihood of detecting a signal at study term was <40%. There was no significant difference between Org 25935 and placebo on percentage heavy drinking days or any other measure of relapse-related drinking behavior. Org 25935 showed no safety issues and was fairly well tolerated, with fatigue, dizziness, and transient visual events as the most commonly occurring side effects. Conclusions: Org 25935 demonstrated no benefit over placebo in preventing alcohol relapse. Study limitations and implications are discussed.

Page Manager: Webmaster|Last update: 9/11/2012
Share:

The University of Gothenburg uses cookies to provide you with the best possible user experience. By continuing on this website, you approve of our use of cookies.  What are cookies?